NUAK1 depletion
absence of NUAK1
overexpressed MYC
MYC overexpression
MYC overexpressing tumour cells
therapeutic potential of NUAK1 suppression
treatment of CRC
driven CRC
CRC cases
attractive target
tumour development
biological consequences of MYC deregulation
Beta-catenin signalling
tumour cell viability
excellent candidate target
colorectal cancer Colorectal cancer
CR tumour initiation
engineered mouse model of sporadic Beta-Catenin
obligate effector of Beta
phosphor-proteomic
combination of proteomic
therapeutic intervention
preliminary results
new treatment strategies
exciting preliminary data
ectopic dependency
culture
inhibition
energetic homeostasis
little-known kinase
ARK5
requirement
mechanism
gut
metabolomics analysis
lack of enzymatic activity
druggable structural features
Hyper-activation of WNT
pre-existing tumours
Murphy lab
ATP levels
therapy
alternative strategy
survival rates
genetic approach
Europeans